Skip Navigation

AIDSInfo-at-a-glance

Issue No. 1 | January 02, 2009
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

Happy New Year!

Welcome to the first issue of AIDSinfo At-a-Glance of 2009!

All of us at AIDSinfo would like to wish you a healthy and happy New Year!

Drug Images Added to Drug Fact Sheets

AIDSinfo recently added images of anti-HIV medications to the drug information fact sheets found in the Drugs section of the Web site. 

Clicking on the drug icon(s) located to the right of a drug's name opens a larger image of the tablet, capsule, or bottle.

Take a look and let us know what you think!

FDA Approves New Pediatric Dosing for Darunavir

On December 18, FDA approved new pediatric dosing recommendations for a new 75 mg Prezista (darunavir) tablet formulation for patients from 6 to less than 18 years of age.

Section 1: Indications and Usage, Section 2: Dosage and Administration, and Section 3: Dosage Forms and Strengths were modified in the labeling information to reflect the changes.

The new labeling information will be available shortly on the FDA Web site.

FDA Approves Pediatric Dosing with Scored Abacavir Tablet

On December 19, FDA approved Ziagen (abacavir) 300 mg scored tablets with corresponding dosing information for pediatric patients weighing 14 kg or more using the scored tablet.

The Dosage and Administration and the Clinical Pharmacology sections of the labeling information were revised to reflect the changes.

The new labeling information will be available shortly on the FDA Web site.

FDA Approves New Nucleic Acid Test for Additional Screening of Donated Blood and Tissue

On December 30, FDA approved "the first nucleic acid test that screens for the presence of two divergent types of HIV in donated blood plasma and tissue."

"The new FDA-approved test detects nucleic acid from HIV-2 and from HIV-1 Group O. ... In addition..., the MPX test simultaneously detects nucleic acid from the most common form of HIV, HIV-1 Group M, as well as the Hepatitis C Virus and the Hepatitis B Virus."

Read the full press release.

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Unsubscribe | Contact Us
Left footer corner image Left footer corner image